Effectiveness of metformin on weight loss in non-diabetic individuals with obesity
- PMID: 23147210
- DOI: 10.1055/s-0032-1327734
Effectiveness of metformin on weight loss in non-diabetic individuals with obesity
Abstract
Objective: The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results. Moreover, the effectiveness in a real-life outpatient setting has not been tested until today. In this study we aimed to examine the effectiveness of metformin as a weight reducing drug in obese and overweight patients with regard to their degree of insulin resistance.
Design and patients: We treated 154 consecutive patients with a body mass index ≥27 kg/m(2) in an outpatient setting over 6 months with metformin up to a dosage of 2,500 mg per day. Additionally, we included 45 untreated patients as controls. Patients were monitored for weight changes over 6 months. Before metformin treatment was started insulin sensitivity was determined in all patients by calculating HOMA index and Matsuda index after a 75 g oral glucose tolerance test.
Results: The mean weight loss in the metformin treated group was 5.8±7.0 kg (5.6±6.5%). Untreated controls gained 0.8±3.5 kg (0.8±3.7%) on average. Patients with severe insulin resistance lost significantly more weight as compared to insulin sensitive patients. The percentage of weight loss was independent of age, sex or BMI.
Conclusion: Metformin is an effective drug to reduce weight in a naturalistic outpatient setting in insulin sensitive and insulin resistant overweight and obese patients.
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.Diabetes Obes Metab. 2008 Jun;10(6):460-7. doi: 10.1111/j.1463-1326.2007.00728.x. Epub 2007 Mar 29. Diabetes Obes Metab. 2008. PMID: 17394563 Clinical Trial.
-
Metformin in the treatment of obesity in subjects with normal glucose tolerance.Rom J Intern Med. 2003;41(3):269-75. Rom J Intern Med. 2003. PMID: 15526510
-
Preliminary report of hypoglycemic response in obese metabolic syndrome males treated with metformin after weight loss intervention.Coll Antropol. 2013 Jun;37(2):367-71. Coll Antropol. 2013. PMID: 23940976 Clinical Trial.
-
Role of metformin for weight management in patients without type 2 diabetes.Ann Pharmacother. 2008 Jun;42(6):817-26. doi: 10.1345/aph.1K656. Epub 2008 May 13. Ann Pharmacother. 2008. PMID: 18477733 Review.
-
Metformin hilft dicken Kids beim Abnehmen.MMW Fortschr Med. 2018 Nov;160(19):38. doi: 10.1007/s15006-018-1083-y. MMW Fortschr Med. 2018. PMID: 30406534 Review. German. No abstract available.
Cited by
-
Effect of metformin and metformin/linagliptin on gut microbiota in patients with prediabetes.Sci Rep. 2024 Apr 27;14(1):9678. doi: 10.1038/s41598-024-60081-y. Sci Rep. 2024. PMID: 38678119 Free PMC article.
-
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.Int J Mol Sci. 2024 Apr 6;25(7):4083. doi: 10.3390/ijms25074083. Int J Mol Sci. 2024. PMID: 38612893 Free PMC article. Review.
-
Cardiovascular autonomic reflex tests using a handheld device in the diagnosis of cardiovascular autonomic neuropathy in patients with schizophrenia.Am Heart J Plus. 2023 Jan 16;26:100252. doi: 10.1016/j.ahjo.2023.100252. eCollection 2023 Feb. Am Heart J Plus. 2023. PMID: 38510185 Free PMC article.
-
Obesity and the kidney: mechanistic links and therapeutic advances.Nat Rev Endocrinol. 2024 Jun;20(6):321-335. doi: 10.1038/s41574-024-00951-7. Epub 2024 Feb 13. Nat Rev Endocrinol. 2024. PMID: 38351406 Review.
-
Lipidomics Profiling of Metformin-Induced Changes in Obesity and Type 2 Diabetes Mellitus: Insights and Biomarker Potential.Pharmaceuticals (Basel). 2023 Dec 11;16(12):1717. doi: 10.3390/ph16121717. Pharmaceuticals (Basel). 2023. PMID: 38139843 Free PMC article.
